Systemic lupus erythematosus: Future therapeutic avenues;Lupus systémique : les traitements du futur

Revue de Medecine Interne

Volumn 29, Issue 9, 2008, Pages 718-724

  Amoura, Z ^a   Haroche, J ^a   Piette, J C ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Systemic lupus erythematosus; Treatment

Indexed keywords

ABATACEPT; ABETIMUS; ALPHA INTERFERON; B CELL ACTIVATING FACTOR; BELIMUMAB; CD20 ANTIBODY; CD22 ANTIGEN; CD40 ANTIGEN; CORTICOSTEROID DERIVATIVE; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; EDRATIDE; EPRATUZUMAB; ETANERCEPT; IMMUNOGLOBULIN G1; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 6; PLACEBO; PROTEIN INHIBITOR; RITUXIMAB; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERANCE; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; SHORT SURVEY; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ARTICLE; DRUG EFFECT; FORECASTING;

B-LYMPHOCYTES; FORECASTING; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 50049125275     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.02.013     Document Type: Short Survey

References (56)

1. Looney R.J. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford) 44 Suppl. 2 (2005) ii13-ii17
2. Silverman G.J., and Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 48 (2003) 1484-1492
3. Cartron G., Watier H., Golay J., and Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
4. Leandro M.J., Edwards J.C., Cambridge G., Ehrenstein M.R., and Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46 (2002) 2673-2677
5. Looney R.J., Anolik J.H., Campbell D., Felgar R.E., Young F., Arend L.J., et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50 (2004) 2580-2589
6. Sfikakis P.P., Boletis J.N., Lionaki S., Vigklis V., Fragiadaki K.G., Iniotaki A., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 52 (2005) 501-513
7. Leandro M.J., Cambridge G., Edwards J.C., Ehrenstein M.R., and Isenberg D.A. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 44 (2005) 1542-1545
8. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., Portales-Perez D., Baranda L., Abud-Mendoza C., et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8 (2006) R83
9. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (Anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2006)
10. Tokunaga M., Fujii K., Saito K., Nakayamada S., Tsujimura S., Nawata M., et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 44 (2005) 176-182
11. Smith K.G., Jones R.B., Burns S.M., and Jayne D.R. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse and retreatment. Arthritis Rheum 54 (2006) 2970-2982
12. Anolik J.H., Campbell D., Felgar R.E., Young F., Sanz I., Rosenblatt J., et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48 (2003) 455-459
13. Cambridge G., Leandro M.J., Teodorescu M., Manson J., Rahman A., Isenberg D.A., et al. B cell depletion therapy in systemic lupus erythematosus: effect on auto-antibody and antimicrobial antibody profiles. Arthritis Rheum 54 (2006) 3612-3622
14. Marks S.D., and Tullus K. Successful outcomes with rituximab therapy for refractory childhood systemic lupus erythematosus. Pediatr Nephrol 21 (2006) 598-599
15. Willems M., Haddad E., Niaudet P., Kone-Paut I., Bensman A., Cochat P., et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 148 (2006) 623-627
16. Saito K., Nawata M., Iwata S., Tokunaga M., and Tanaka Y. Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus. Rheumatology (Oxford) 44 (2005) 1462-1464
17. Tahir H., Rohrer J., Bhatia A., Wegener W.A., and Isenberg D.A. Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. Rheumatology (Oxford) 44 (2005) 561-562
18. Otipoby K.L., Andersson K.B., Draves K.E., Klaus S.J., Farr A.G., Kerner J.D., et al. CD22 regulates thymus-independent responses and the lifespan of B cells. Nature 384 (1996) 634-637
19. Dorner T., Kaufmann J., Wegener W.A., Teoh N., Goldenberg D.M., and Burmester G.R. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 8 (2006) R74
20. Khare S.D., Sarosi I., Xia X.Z., McCabe S., Miner K., Solovyev I., et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 97 (2000) 3370-3375
21. Gross J.A., Johnston J., Mudri S., Enselman R., Dillon S.R., Madden K., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
22. Zhang J., Roschke V., Baker K.P., Wang Z., Alarcon G.S., Fessler B.J., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166 (2001) 6-10
23. Liu W., Szalai A., Zhao L., Liu D., Martin F., Kimberly R.P., et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 50 (2004) 1884-1896
24. Cheema G.S., Roschke V., Hilbert D.M., and Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44 (2001) 1313-1319
25. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 48 (2003) 3253-3265
26. Fieschi C., Malphettes M., Galicier L., and Oksenhendler E. Adult-onset primary hypogammaglobulinemia. Presse Med 35 (2006) 887-894
27. Weisman M.H., Bluestein H.G., Berner C.M., and de Haan H.A. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 24 (1997) 314-318
28. Furie R.A., Cash J.M., Cronin M.E., Katz R.S., Weisman M.H., Aranow C., et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 28 (2001) 257-265
29. Alarcon-Segovia D., Tumlin J.A., Furie R.A., McKay J.D., Cardiel M.H., Strand V., et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 48 (2003) 442-454
30. Merrill J.T. LJP 1082: a toleragen for Hughes syndrome. Lupus 13 (2004) 335-338
31. Sthoeger Z.M., Dayan M., Tcherniack A., Green L., Toledo S., Segal R., et al. Modulation of autoreactive responses of peripheral blood lymphocytes of patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies. Clin Exp Immunol 131 (2003) 385-392
32. Eilat E., Dayan M., Zinger H., and Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci U S A 98 (2001) 1148-1153
33. Sharabi A., Zinger H., Zborowsky M., Sthoeger Z.M., and Mozes E. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci U S A 103 (2006) 8810-8815
34. Desai-Mehta A., Lu L., Ramsey-Goldman R., and Datta S.K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97 (1996) 2063-2073
35. Yellin M.J., D'Agati V., Parkinson G., Han A.S., Szema A., Baum D., et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 40 (1997) 124-134
36. Kalled S.L., Cutler A.H., Datta S.K., and Thomas D.W. Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 160 (1998) 2158-2165
37. Early G.S., Zhao W., and Burns C.M. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 157 (1996) 3159-3164
38. Kalunian K.C., Davis Jr. J.C., Merrill J.T., Totoritis M.C., and Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 3251-3258
39. Boumpas D.T., Furie R., Manzi S., Illei G.G., Wallace D.J., Balow J.E., et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48 (2003) 719-727
40. Kawai T., Andrews D., Colvin R.B., Sachs D.H., and Cosimi A.B. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6 (2000) 114
41. Finck B.K., Linsley P.S., and Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 265 (1994) 1225-1227
42. Daikh D.I., and Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 166 (2001) 2913-2916
43. Weinblatt M., Combe B., Covucci A., Aranda R., Becker J.C., and Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
44. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
45. Llorente L., and Richaud-Patin Y. The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 20 (2003) 287-289
46. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43 (2000) 1790-1800
47. Koutouzov S., Mathian A., and Dalloul A. Type-I interferons and systemic lupus erythematosus. Autoimmun Rev 5 (2006) 554-562
48. Mathian A., Weinberg A., Gallegos M., Banchereau J., and Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black x New Zealand White) F1 but not in BALB/c mice. J Immunol 174 (2005) 2499-2506
49. Tackey E., Lipsky P.E., and Illei G.G. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 13 (2004) 339-343
50. Fragoso-Loyo H., Richaud-Patin Y., Orozco-Narvaez A., Davila-Maldonado L., Atisha-Fregoso Y., Llorente L., et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 56 (2007) 1242-1250
51. Liang B., Gardner D.B., Griswold D.E., Bugelski P.J., and Song X.Y. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119 (2006) 296-305
52. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Auto-immune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 86 (2007) 242-251
53. Aringer M., and Smolen J.S. SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther 5 (2003) 172-177
54. Aringer M., and Smolen J.S. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 13 (2004) 344-347
55. Aringer M., Graninger W.B., Steiner G., and Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50 (2004) 3161-3169
56. Aringer M., Steiner G., Graninger W.B., Hofler E., Steiner C.W., and Smolen J.S. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum 56 (2007) 274-279